StratifiCare is a medtech startup dedicated to transforming cancer care through high-precision, single-cell predictive solutions. Powered by multi-parametric flow cytometry workflows, StratifiCare analyses complex immune biomarkers from a simple blood draw to decode distinct signatures linked to radiation-induced tumor priming. Its product, StratifiREY, provides oncology teams with a proprietary complementary diagnostic to accurately predict patient response to transarterial radioembolization and its synergistic combinations with immune-oncology drugs.

By guiding dual-therapy sequencing and eliminating trial-and-error treatment pathways before procedures begin, StratifiCare continues to advance precision oncology to improve global treatment outcomes and clinical efficiency.

VISIT WEBSITE

For further enquiry, please contact Anthony Chua (Co-Founder & CEO).